Eli Lilly and Company (NYSE:LLY) Shares Acquired by Chicago Capital LLC

Chicago Capital LLC raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 43.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 38,522 shares of the company’s stock after buying an additional 11,709 shares during the quarter. Chicago Capital LLC’s holdings in Eli Lilly and Company were worth $29,739,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of LLY. Algert Global LLC increased its holdings in shares of Eli Lilly and Company by 27.9% during the 2nd quarter. Algert Global LLC now owns 504 shares of the company’s stock valued at $456,000 after purchasing an additional 110 shares in the last quarter. AMF Tjanstepension AB increased its holdings in shares of Eli Lilly and Company by 113.7% during the 3rd quarter. AMF Tjanstepension AB now owns 331,786 shares of the company’s stock valued at $293,964,000 after purchasing an additional 176,552 shares in the last quarter. Czech National Bank increased its holdings in shares of Eli Lilly and Company by 5.6% during the 3rd quarter. Czech National Bank now owns 160,697 shares of the company’s stock valued at $142,368,000 after purchasing an additional 8,566 shares in the last quarter. Azzad Asset Management Inc. ADV increased its holdings in shares of Eli Lilly and Company by 11.3% during the 3rd quarter. Azzad Asset Management Inc. ADV now owns 1,931 shares of the company’s stock valued at $1,711,000 after purchasing an additional 196 shares in the last quarter. Finally, Versant Capital Management Inc increased its holdings in shares of Eli Lilly and Company by 9.4% during the 3rd quarter. Versant Capital Management Inc now owns 979 shares of the company’s stock valued at $867,000 after purchasing an additional 84 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Trading Up 2.1 %

Shares of LLY stock opened at $827.41 on Wednesday. The company’s 50-day moving average price is $784.69 and its 200-day moving average price is $843.49. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The stock has a market cap of $785.48 billion, a price-to-earnings ratio of 89.45, a PEG ratio of 1.72 and a beta of 0.42. Eli Lilly and Company has a twelve month low of $682.53 and a twelve month high of $972.53.

Eli Lilly and Company declared that its board has approved a share buyback plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 2% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be given a dividend of $1.50 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.73%. Eli Lilly and Company’s payout ratio is presently 56.22%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. StockNews.com lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday, January 30th. Citigroup cut their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Bank of America reissued a “buy” rating and issued a $997.00 price target on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Deutsche Bank Aktiengesellschaft cut their price target on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a report on Monday, November 4th. Finally, Wolfe Research started coverage on shares of Eli Lilly and Company in a report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price target for the company. Five analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $997.50.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.